These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Not reported Terminated||2004-002821-30||Study of the efficacy of intravesical instillations of interleukin-2 in treatment of superficial bladder cancer||2009-04-16||due-trials|
|Ongoing||2004-003906-81||Chemoradiation with once weekly gemcitabine for invasive bladder cancer||not-yet-due|
|Not reported||2007-001818-16||Phase II Study of High-dose Methylprednisolone and Rituximab in Previously Treated Patients with High Risk Chronic B Lymphocytic Leukemia||2011-12-16||due-trials|
|Reported results||2008-006309-17||Significance of prognostic and predictive factors for the efficacy and safety of neoadjuvant chemotherapy in combination with chemoradiation administered in patients with locally advanced cervical can...||2013-10-01||due-trials|
|Not reported||2010-023205-35||Study of Rituximab in Addition to Glucocorticoid in Pretreated Elderly or Unfit Patients with Chronic B Lymphocytic Leukemia||2016-01-06||due-trials|
|Not reported Terminated||2011-000908-18||Treatment Protocol for young adults (18-45 years of age) with Acute Lymphoblastic Leukemia||2016-04-21||due-trials|
|Ongoing||2019-000661-20||Ivabradine to prevent anthracycline-induced cardiotoxicity: a prospective randomized open label clinical trial. Ivabradino įtaka kardiotoksinės chemoterapijos indukuotos ankstyvosios miokardo pažai...||not-yet-due|
|Other||2020-001366-11||An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care||not-yet-due|
|Ongoing||2020-005128-12||An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients with Mild Pneumonia − An open-label randomized controlled study||not-yet-due|
|Ongoing||2020-005214-18||An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients without Pneumonia − An open-label randomized controlled study||not-yet-due|